This course has expired. You can still review the content but course credit is no longer available.
Diabetes is a growing epidemic in the United States, and diabetic macular edema (DME) and diabetic retinopathy (DR) poses a substantial risk for vision loss if not diagnosed and/or treated. It remains clear that although diabetes is a systemic disorder, the manifestations of diabetic complications will occur without optimal glycemic and blood pressure control. Optometrists can help continually reinforce that message by educating patients about the necessity for ongoing and yearly dilated eye exams, and discussing the potential treatments should vision loss become obvious.
This CE activity is supported through an unrestricted educational grant from Regeneron Pharmaceuticals, Inc.
This CE activity is supported by The University of Houston College of Optometry
This activity intends to educate optometrists.
Upon completion of this activity, participants should be better able to:
This course is COPE approved for 1.0 hour of CE credit for optometrists.
COPE Course ID: 49883-SD
COPE Event ID: 111606
Mark Dunbar, OD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Allergan, Inc.; Carl Zeiss Meditec and Regeneron Pharmaceuticals, Inc.
Paul Chous, OD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Bausch & Lomb Incorporated; CooperVision; Freedom Meditech, Inc.; Regeneron Pharmaceuticals, Inc.; and ZeaVision, LLC and Grant/Research Support: ZeaVision, LLC
Leo Semes, OD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Alcon; Allergan, Inc.; Optovue, Inc.; and Regeneron Pharmaceuticals, Inc. and Stock/Shareholder: HPO
Cheryl Cavanaugh, MS; Michelle Dalton and Melanie Lawler, PhD have no relevant commercial interests to disclose.
Each of the contributing faculty listed above has attested to the following:
1. That the relationships/affiliations noted will not bias or otherwise influence his or her involvement in this activity;
2. That practice recommendations given relevant to the companies with whom he or she has relationships/affiliations will be supported by the best available evidence or, absent evidence, will be consistent with generally accepted medical practice; and
3. That all reasonable clinical alternatives will be discussed when making practice recommendations.
Off Label Disclosure
Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.